The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
Background Secukinumab, a fully human immunoglobulin G1-kappa monoclonal antibody that directly inhibits interleukin (IL)-17A, has been shown to have robust efficacy in the treatment of moderate-to-severe psoriasis (PsO), psoriatic arthritis (PsA), and ankylosing spondylitis (AS) demonstrating a rapid onset of action and sustained long-term clinical responses with a consistently favorable safety profile...
Die Psoriasis wird zu den chronisch entzündlichen Erkrankungen gezählt, bei deren Pathogenese Th1-vermittelten Immunphänomenen eine wesentliche Rolle zugeschrieben wird. Infliximab ist ein chimärer monoklonaler Antikörper gegen das Th1-Zytokin TNF-α, der bereits für die Therapie der Psoriasisarthritis (als Kombinationstherapie mit Methotrexat) zugelassen ist. In klinischen Studien zur Psoriasis vulgaris...
Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.